-Intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as...
–Recently announced positive Phase 2 topline data in Major Depressive Disorder (“MDD”) with 79% of patients in remission from depression after two...
Newly issued patent expected to provide protection until at least 2041 and includes composition of matter claims to pharmaceutical compositions within...
Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses. The...
New patent provides IP protection until at least 2041. Cybin’s patent portfolio now includes 39 granted patents and over 170 pending applications. The...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
–Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET – – Complete Phase 2...
This morning we received interim results on Cybin’s Phase 2 trial using its CYB003 psilocybin compound for depression. And they did not disappoint. The...
– European patent provides composition of matter and medical use protection for the Company’s proprietary deuterated psilocybin analog and deuterated...
Cybin has added to this growing IP portfolio with the granting of two more patents for its DMT program. The post Cybin Granted Two New Patents...